Key facts
- Vestal Point Capital, LP filed SCHEDULE 13G for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX).
- Disclosed ownership: 6.3%.
- Date of event: 31 Mar 2026.
Vestal Point Capital, LP - 31 Mar 2026 SCHEDULE 13G Report for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX)
- Symbol
- NRIX
- Shares outstanding
- 103,174,603 shares
- Disclosed shares
- 6,500,000 shares
- Ownership percentage
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 17:01:34 UTC
- Event date
- 31 Mar 2026
- SEC filing
- View on sec.gov
Subject security
Ownership signal
SEC evidence
Key filing fact
Vestal Point Capital, LP disclosed 6.3% ownership in Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 17:01.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 6.3% | 6,500,000 | 0 | 6,500,000 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 6.3% | 6,500,000 | 0 | 6,500,000 | /s/ Ryan Wilder | Ryan Wilder, Individually |
CIK / CUSIP context first